|
|
URGN
Jul 13, 2021 14:13:11 GMT
via mobile
Post by free air on Jul 13, 2021 14:13:11 GMT
Has anyone done DD on urogen (URGN)? It has one FDA approval and is currently doing phase 3 for NMIBC which has a larger patient population. Data looks promising however the stock price is trending down. I’m new to biotech so not sure if this a good time to get in or if I’m missing something…
|
|
|
|
URGN
Jul 13, 2021 16:14:03 GMT
via mobile
Post by magnus123 on Jul 13, 2021 16:14:03 GMT
Has anyone done DD on urogen (URGN)? It has one FDA approval and is currently doing phase 3 for NMIBC which has a larger patient population. Data looks promising however the stock price is trending down. I’m new to biotech so not sure if this a good time to get in or if I’m missing something… It's an Israeli company. Never buy israeli bio stocks. |
|
|
|
URGN
Jul 13, 2021 16:46:12 GMT
via mobile
Post by free air on Jul 13, 2021 16:46:12 GMT
Has anyone done DD on urogen (URGN)? It has one FDA approval and is currently doing phase 3 for NMIBC which has a larger patient population. Data looks promising however the stock price is trending down. I’m new to biotech so not sure if this a good time to get in or if I’m missing something… It's an Israeli company. Never buy israeli bio stocks. What is the reason? |
|
|
|
URGN
Jul 13, 2021 16:57:33 GMT
Post by magnus123 on Jul 13, 2021 16:57:33 GMT
|
|
|
|
URGN
Jul 13, 2021 16:58:25 GMT
Post by magnus123 on Jul 13, 2021 16:58:25 GMT
What I read about URGN sounds promising, but I wouldn't touch it.
|
|
|
|
URGN
Jul 13, 2021 17:26:08 GMT
Post by lcd on Jul 13, 2021 17:26:08 GMT
It is a pretty small sample size, but BCLI, KTOV, and RDHL (I think there was one more too?) have all been covered on this board (and I have owned each at some point in the past too) and they all not only didn't live up to potential, but they also seem sketchy. The article magnus linked is a good description.
I wouldn't avoid buying an Israeli biotech in the future, but I will hold them to a higher standard of demonstrated success before investing.
|
|
|
|
URGN
Jul 13, 2021 18:16:31 GMT
lcd likes this
Post by magnus123 on Jul 13, 2021 18:16:31 GMT
It is a pretty small sample size, but BCLI, KTOV, and RDHL (I think there was one more too?) have all been covered on this board (and I have owned each at some point in the past too) and they all not only didn't live up to potential, but they also seem sketchy. The article magnus linked is a good description. I wouldn't avoid buying an Israeli biotech in the future, but I will hold them to a higher standard of demonstrated success before investing. It's special for a israeli biotech that URGNs last offering was in Jan 2019. $150 Million raised at $41 / share with Goldman and Morgan Stanley. I need to take a closer look into this company. |
|
|
|
URGN
Jul 30, 2021 8:19:53 GMT
via mobile
lcd likes this
Post by free air on Jul 30, 2021 8:19:53 GMT
|
|
